BIIB vs. TAK: Biogen vs. Takeda Pharmaceutical Stock Comparison

Company Profile

Biogen (BIIB) and Takeda Pharmaceutical (TAK) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BIIB is classified in Biotechnology while TAK is classified in Pharmaceuticals.

Biogen (BIIB) trades as ordinary local shares, while Takeda Pharmaceutical (TAK) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Takeda Pharmaceutical (TAK) reports a negative beta of -0.01, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Biogen (BIIB) has a non-negative beta of 0.08.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Biogen (BIIB) at 1.87% and Takeda Pharmaceutical (TAK) at 0.56% land near their industries’ usual ROE ranges, so capital efficiency looks broadly in line with peers on both sides.

Both Biogen (BIIB) at 3.38% and Takeda Pharmaceutical (TAK) at 0.87% keep about the typical share of revenue as profit for their industries — neither bottom line stands out from peers.

Both Biogen (BIIB) at 24.12% and Takeda Pharmaceutical (TAK) at 24.55% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Biogen (BIIB) at 2.22% is around its peer norm for revenue growth, while Takeda Pharmaceutical (TAK) at -1.66% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Takeda Pharmaceutical (TAK) at 77.96% sits in the top EPS growth quartile, while Biogen (BIIB) at -21.38% is closer to the peer norm — faster per-share earnings growth for TAK.

Growth Metrics

Financial Strength

Both Biogen (BIIB) at 1.95 and Takeda Pharmaceutical (TAK) at 1.15 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Biogen (BIIB) at 0.41 carries an industry-typical debt-to-equity mix, while Takeda Pharmaceutical (TAK) at 0.72 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Biogen (BIIB) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Takeda Pharmaceutical (TAK) reports a yield of 953.28%, ranking against industry peers normally.

Takeda Pharmaceutical (TAK) reports payout ratio above 100% at 426.53%, meaning dividends exceeded current-period earnings; Biogen (BIIB) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

Both Biogen (BIIB) at 107.51 and Takeda Pharmaceutical (TAK) at 300.29 trade above their industries’ P/E ratio peer ranges, pointing to unusually expensive trailing earnings relative to peers.

Takeda Pharmaceutical (TAK) at 0.01 sits in the cheaper P/S ratio quartile while Biogen (BIIB) at 3.57 prices around its industry’s middle — TAK costs less per dollar of sales, though read it alongside growth and margins.

Takeda Pharmaceutical (TAK) at 1.43 sits in the lower P/B ratio quartile against book while Biogen (BIIB) at 1.94 is valued near its industry’s middle — TAK is cheaper on assets, though weigh it against ROE and asset quality.

Valuation Metrics